Abstract:Importance Patient-directed educational materials are a promising implementation strategy to expand deprescribing reach and adoption, but little is known about the impact across medication groups with potentially different perceived risks. Objective To examine the impact of a patient-directed education intervention on clinician deprescribing of potentially low-benefit (proton pump inhibitors) or high-risk medications (high-dose gabapentin, diabetes agents with hypoglycemia risks). Design, Setting, and Participants This pragmatic multisite nonrandomized clinical trial took place at 3 geographically distinct US Veterans Affairs (VA) medical centers from April 2021 to October 2022. The total study sample was composed of the intervention cohort and the historical control cohort cared for by 103 primary care practitioners (PCPs). Intervention The primary intervention component was a medication-specific brochure, mailed during the intervention time frame to all eligible patients 2 to 3 weeks prior to upcoming primary care appointments. Patients seen by the same PCPs at the same sites 1 year prior to the study intervention served as controls. Main Outcome and Measures The primary binary outcome variable was deprescribing 6 months after the intervention, defined as complete cessation or any dose reduction of the target medication using VA pharmacy dispensing data. Results The total study sample included 5071 patients. The overall rate of deprescribing among the intervention cohort (n = 2539) was 29.5% compared with 25.8% among the controls (n = 2532). In an unadjusted model, the intervention cohort was statistically significantly more likely to have deprescribing (odds ratio [OR], 1.17 [95% CI, 1.03-1.33]; P = .02). In a multivariable logistic regression model nesting patients within PCPs within sites and controlling for patient and PCP characteristics, the odds of deprescribing in the intervention cohort were 1.21 times that of the control cohort (95% CI, 1.05-1.38; P = .008). The difference in deprescribing prevalence between the intervention and control cohorts (proton pump inhibitors: 29.4% vs 25.4%; gabapentin: 40.2% vs 36.2%; hypoglycemia risk: 27.3% vs 25.1%) did not statistically significantly differ by medication group ( P = .90). Conclusion and Relevance This nonrandomized clinical trial found that patient-directed educational materials provided prior to scheduled primary care appointments can effectively promote deprescribing for potentially low-benefit and high-risk medication groups. Trial Registration ClinicalTrials.gov Identifier: NCT0429490

[Deprescribing proton pump inhibitors : what are the clinical practice guidelines ?]

Approaches to Deprescribing Proton Pump Inhibitors in Clinical Practice: A Systematic Review

Deprescribing Proton Pump Inhibitors: Updated Clinical Guidelines

How could proton pump inhibitors de-prescription be managed in geriatric long-term care?

Improving the feasibility of deprescribing proton pump inhibitors: GPs' insights on barriers, facilitators, and strategies

The Use and Misuse of Proton Pump Inhibitors: An Opportunity for Deprescribing

Proton Pump Inhibitors: Rational Use and Use-Reduction – The Windsor Workshop

Development and validation of a training course on proton pump inhibitor deprescription for general practitioners in a rural continuing medical education program: a pilot study

Prescribing practices for Proton pump inhibitors among primary care physicians in England

De-Prescribing Proton Pump Inhibitors in Patients With End Stage Kidney Disease: A Quality Improvement Project

Deprescribing of proton pump inhibitors in older patients: A cost-effectiveness analysis

A review of proton pump inhibitor use in cystic fibrosis and considerations for deprescribing

Primary and Specialty Care Trainees’ Perceptions About Proton Pump Inhibitor Use

Patient-Directed Education to Promote Deprescribing

Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist's geriatric assessment

Guidelines on optimizing the use of proton pump inhibitors: PPI stewardship

Rationale use of proton pump inhibitors: Observational study of hospital based prescriptions and role of clinical pharmacist

Deprescribing bisphosphonates in the osteoporosis treatment in older people

Deprescribing in hospitalized patients with cancer: A clinical pharmacist-initiated multidisciplinary intervention

Implementation considerations of deprescribing interventions: A scoping review

Identification of Potentially Inappropriate Medications in Frail Older Adults Residing in Long-Term Care: A Retrospective Chart Review Study